New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging

Frontiers in Cardiovascular Medicine

article

Farah Cadour¹  Franck Thuny³  Joevin Sourdon¹ 

[1] Aix-Marseille Université;APHM, Hôpital Universitaire Timone;Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, North Hospital, Assistance Publique - Hôpitaux de Marseille, Centre for CardioVascular and Nutrition Research

关键词: cardio-oncology;    cardiotoxicity;    perfusion;    metabolism;    mitochondria;    magnetic resonance spectroscopy or MRS;    magnetic resonance imaging;    nuclear imaging;   

DOI  :  10.3389/fcvm.2022.813883

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Cardio-oncology requires a good knowledge of the cardiotoxicity of anticancer drugs, their mechanisms, and their diagnosis for better management. Anthracyclines, anti-vascular endothelial growth factor (VEGF), alkylating agents, antimetabolites, anti-human epidermal growth factor receptor (HER), and receptor tyrosine kinase inhibitors (RTKi) are therapeutics whose cardiotoxicity involves several mechanisms at the cellular and subcellular levels. Current guidelines for anticancer drugs cardiotoxicity are essentially based on monitoring left ventricle ejection fraction (LVEF). However, knowledge of microvascular and metabolic dysfunction allows for better imaging assessment before overt LVEF impairment. Early detection of anticancer drug-related cardiotoxicity would therefore advance the prevention and patient care. In this review, we provide a comprehensive overview of the cardiotoxic effects of anticancer drugs and describe myocardial perfusion, metabolic, and mitochondrial function imaging approaches to detect them before over LVEF impairment.

【 授权许可】

CC BY